Sector News

Big pharma agrees to drastically cut prices of blockbuster drugs in China

December 2, 2019
Life sciences

China’s National Healthcare Security Administration (NHSA) has announced it has agreed an average 61% cut in prices of 70 top-selling drugs with large pharma manufacturers in exchange for inclusion on a state-run insurance scheme list.

According to the South China Morning Post, the 70 drugs include Roche’s Perjeta, Novartis’ Xolair and the top selling drug in the world AbbVie’s Humira, as well as Eli Lilly and China-based Innovent Biologics’ Tyvyt.

However, some top selling anti-programmed cell death-1 (PD-1) drugs were not included in this list – Bristol-Myers Squibb’s Opdivo and Merck’s Keytruda, which are both approved in China – an analyst explains to the Financial Times (FT) this is to allow domestic pharma companies to be able to compete in this lucrative area of the oncology market.

The FT also listed AstraZeneca, Gilead, Sanofi and Roche among big pharma who agreed to slash their drug prices.

State-owned news organisation Xinhua noted that 22 anti-cancer drugs, seven drugs for rare diseases, 14 for chronic diseases, four for paediatric indications and three for hepatitis were reduced in price by 87%.

In addition, the FT reported 27 drugs already reimbursed through the scheme have had their prices further reduced by an average 26%.

The NHSA claims this makes the prices of these drugs the lowest in the world. Also, this agreements means big pharma and their drugs will have greater access to the world’s second largest pharma market because more Chinese citizens in smaller, more remote cities will be able to afford the drugs through their state medical insurance system.

Big pharma has been making overtures to China over the last few years since the Chinese Government began to open up the country’s healthcare system in 2015. Over the past year, companies have been expanding their R&D presence in China and signing various deals with domestic biotechs.

By Allie Nawrat

Source: Pharmaceutical Technology

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.